Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Novo Nordisk Plan NASH Collaboration

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2019 | 06:26am EDT

By Colin Kellaher

Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NOVO-B.KO, NVO) on Friday said they will collaborate on a clinical trial combining compounds from their pipelines in nonalcoholic steatohepatitis, a chronic liver condition commonly known as NASH.

The companies said the trial will be a proof-of-concept study combining Novo's semaglutide and Gilead's cilofexor and firsocostat for the treatment of patients with NASH.

Gilead, a Foster City, Calif., biopharmaceutical company, and Danish pharmaceutical company Novo said they also may collaborate on preclinical research to advance understanding of the disease, which often affects people with diabetes and metabolic syndrome.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES 0.70% 66.42 Delayed Quote.6.19%
NOVO NORDISK AS 2.59% 358.5 Delayed Quote.17.30%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09/16A Plan to Fight Hep C -- WSJ
DJ
09/12GILEAD SCIENCES : Ex-dividend day for
FA
09/09GILEAD SCIENCES : and the Elton John AIDS Foundation Launch RADIAN Initiative to..
BU
08/29GILEAD SCIENCES : An amendment to a SC 13D filing
PU
08/29AGENUS : Triggers 3rd Milestone in its Collaboration with Gilead
AQ
08/29GILEAD SCIENCES : Report
CO
08/27GILEAD SCIENCES INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/26GILEAD SCIENCES : to Present at the Morgan Stanley Global Healthcare Conference ..
BU
08/26GILEAD SCIENCES : Alberta Provides Access to Biktarvy® for the Treatment of HIV
AQ
08/26GILEAD SCIENCES : And galapagos complete closing of their transformative researc..
AQ
More news
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 272 M
Debt 2019 3 023 M
Yield 2019 3,79%
P/E ratio 2019 18,9x
P/E ratio 2020 11,6x
EV / Sales2019 3,91x
EV / Sales2020 3,76x
Capitalization 84 118 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,52  $
Last Close Price 66,42  $
Spread / Highest target 43,0%
Spread / Average Target 21,2%
Spread / Lowest Target -9,67%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES6.19%84 118
VERTEX PHARMACEUTICALS7.49%45 783
REGENERON PHARMACEUTICALS-20.78%32 375
GENMAB29.51%13 425
NEUROCRINE BIOSCIENCES, INC.41.20%9 234
HUALAN BIOLOGICAL ENGINEERING INC--.--%6 523